<DOC>
	<DOCNO>NCT00729898</DOCNO>
	<brief_summary>This study conduct Europe . The study aim observe incidence serious adverse drug reaction patient type 2 diabetes NovoMix® 30 treatment .</brief_summary>
	<brief_title>Observational Study Observe Safety NovoMix® 30 Treatment Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Any patient diabetes type 2 diabetes Currently treat basal human insulin therapy ( basal combination oral glucose lower drug insulin Selection patient discretion treat physician decision prescribe one study product patient Known suspect allergy study product ( ) relate product Pregnancy , breastfeed intention become pregnant within next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>